TL;DR
This study reveals a crucial crosstalk between ovarian cancer stem cells (CSCs) and tumor-associated macrophages (TAMs) mediated by the WNT signaling pathway. This interaction fuels CSC stemness, chemoresistance, and invasiveness, suggesting WNT signaling as a promising therapeutic target to combat aggressive ovarian cancer.
What Problem Does This Paper Address?
Ovarian cancer, particularly in its advanced stages, often involves malignant ascites where cancer cells, especially cancer stem cells (CSCs), interact with immune cells like macrophages. These interactions are thought to drive tumor progression and resistance to treatment. While it's known that macrophages can adopt a pro-tumoral (M2-like) phenotype and that CSCs are crucial for tumor recurrence, the precise mechanisms of their reciprocal interaction, particularly in the context of the ascites microenvironment, remain unclear. This paper aims to dissect this complex interplay, focusing on how CSCs and M2 macrophages influence each other and contribute to aggressive tumor phenotypes, with a specific interest in the role of WNT signaling.
Methods
The researchers employed a sophisticated 3D hanging-drop hetero-spheroid model to mimic the ascites microenvironment, allowing close co-culture of ovarian cancer stem cells (derived from the OVCAR3 cell line) and monocyte-derived macrophages (from U937 cell line or peripheral blood mononuclear cells - PBMCs).
Key techniques included:
- Flow Cytometry: To assess macrophage polarization (CD68, CD206 markers) and CSC stemness (ALDH activity).
- Quantitative Polymerase Chain Reaction (qPCR): To measure gene expression levels of cytokines (IL-10, IL-6) and WNT ligands.
- Enzyme-Linked Immunosorbent Assay (ELISA): To quantify secreted cytokines (IL-10, IL-6).
- Transwell Assays: To evaluate the invasive potential of spheroids.
- MTS Assay: To assess chemoresistance to carboplatin.
- Western Blotting: To detect protein expression (e.g., β-catenin).
- shRNA Knockdown: To specifically silence WNT5B expression in macrophages.
- In vivo Xenograft Models: Using NSG mice to assess tumor initiation and growth kinetics of conditioned CSCs.
- Pharmacological Inhibition: Using WNT secretion inhibitors (IWP-2) and IL-6 signaling inhibitors (Ruxolitinib, sc144, Tocilizumab).
The use of the 3D hanging-drop model is a significant aspect, as it better recapitulates the anchorage-independent growth of CSCs in ascites compared to traditional 2D cultures.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- CSCs drive M2 macrophage polarization: Ovarian CSCs, more so than bulk cancer cells, induce a pro-tumoral (M2-like) phenotype in macrophages, evidenced by increased CD206 expression. This suggests CSCs actively shape the immune microenvironment to their advantage.
- Macrophages promote CSC stemness: M2 macrophages, in turn, enhance the maintenance of CSC stemness, indicated by increased ALDH activity. This creates a positive feedback loop where CSCs foster an immunosuppressive environment, and this environment then supports CSC self-renewal.
- WNT signaling is a critical mediator: The study strongly implicates the WNT pathway in this reciprocal interaction. CSC-derived WNT ligands promote M2 macrophage activation, and conversely, macrophage-derived WNT ligands (particularly WNT5B) drive CSC stemness and associated phenotypes.
- Macrophage WNT5B is key for CSC enrichment: Knocking down WNT5B in macrophages significantly reduced CSC stemness (ALDH activity) and reversed some of the pro-tumoral effects, highlighting WNT5B as a crucial factor in macrophage-CSC crosstalk.
- The CSC-TAM axis fuels aggressive phenotypes: The combined effects of CSCs and M2 macrophages, mediated by WNT and IL-6 signaling, lead to increased chemoresistance, invasiveness, and tumorigenicity in vivo.
Key Results
- Increased CD206 expression: CSC co-culture with M0 macrophages led to a significant 20% increase in CD206 expression compared to bulk OVCAR3 cells.
- Elevated IL-10 and IL-6: CSC/M2 hetero-spheroids showed significantly higher levels of IL-10 and IL-6 cytokines.
- Chemoresistance and invasiveness: CSC/M2 hetero-spheroids were significantly more resistant to carboplatin and 2-2.6 fold more invasive than CSC mono-spheroids.
- WNT5B knockdown effects: Knockdown of macrophage WNT5B led to a >5-fold decrease in ALDH+ CSCs, increased sensitivity to carboplatin, and reduced invasiveness.
- In vivo tumorigenicity: CSCs conditioned by M2 macrophages showed significantly faster tumor initiation and growth kinetics in NSG mice compared to control CSCs.
- Tocilizumab resistance: CSC/M2 tumors were significantly more resistant to Tocilizumab (IL-6 inhibitor) treatment compared to CSC mono-spheroids.
Limitations and Future Work
- In vitro model limitations: While the 3D hanging-drop model effectively mimics aspects of the ascites microenvironment, it is still an in vitro system and may not fully capture the complexity of the in vivo tumor microenvironment.
- Specificity of WNT ligands: While WNT5B was highlighted, the study also noted elevated expression of other WNT ligands in CSCs and their co-cultures, suggesting a broader role for WNT signaling. Further investigation into the specific contributions of each WNT ligand could be beneficial.
- Therapeutic translation: The authors suggest the WNT pathway as a potential therapeutic target. Future work could focus on developing and testing specific WNT inhibitors or combination therapies that target both CSCs and TAMs to reduce tumor burden and prevent recurrence. Investigating the impact of this interaction on other immune cell populations within the tumor microenvironment, such as T cells, is also a promising avenue.
Summary updated